Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Citi
US Army
Mallinckrodt
Cerilliant
Julphar
Baxter
Medtronic
McKesson

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 3,726,977

« Back to Dashboard

Title: 2-NITRO-11-(1-PIPERAZINYL)-DIBENZ (b,f) (1,4) OXAZEPINES COMPOSITIONS IN THE TREATMENT OF DEPRESSION
Abstract:Pharmaceutical compositions containing 2-nitro-11-(1-piperazinyl)-dibenz [b,f] [1,4] oxazepine or its pharmaceutically acceptable acid addition salts are useful in the treatment of depression.
Inventor(s): Schmutz; Jean (Muri, CH), Hunziker; Fritz (Berne, CH), Kunzle; Franz Martin (Berne, CH)
Assignee: Sandoz-Wander, Inc. (Hanover, NJ)
Filing Date:Nov 01, 1971
Application Number:05/194,515
Claims:1. A method for treating depression, which comprises enterally or parenterally administering to a mammal in need of said treatment an anti-depressant effective amount of 4-nitro-11-(1-piperazinyl)-dibenz [b,f][1,4]oxazepine or a pharmaceutically acceptable acid addition salt thereof.

2. A method according to claim 1 wherein 2-nitro-11-(1-piperazinyl)-dibenz [b,f][1,4] oxazepine or a pharmaceutically acceptable acid addition salt thereof is administered to a mammal in need of said treatment at a daily dose of from about 5 milligrams to about 400 milligrams.

3. A method according to claim 1 wherein 2-nitro-11-(1-piperazinyl)-dibenz [b,f] [1,4] oxazepine or a pharmaceutically acceptable acid addition salt thereof is administered to a mammal in need of said treatment in a unit dosage form comprising said 2-nitro-11-(1-piperazinyl)-dibenz [b,f] [1,4] oxazepine or a pharmaceutically acceptable acid addition salt thereof to the extent of from about 10 milligrams to about 25 milligrams per unit dosage.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Federal Trade Commission
Baxter
Deloitte
Citi
Queensland Health
Mallinckrodt
Merck
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.